OBJECTIVE: To evaluate the QoL of lg-NHL patients enrolled in a trial comparing the efficacy and safety of F and CVP. METHODS: The EORTC-QLQ-C30 (v1) questionnaire was completed by all French and English literate patients at baseline, during treatment, and after treatment. QoL was expressed as a global health status (QL) and 5 functional scores (FS); physical, emotional, social (SF), cognitive (CF) and role (RF) for which high values indicate better QoL. It was also expressed as 8 symptom/single item (SSI) scores: fatigue, nausea and vomiting (NV), pain, dyspnea (DY), insomnia, appetite loss, constipation (CO), diarrhea (DI), and financial difficulties (FI) for which lower values mean better QoL. RESULTS: Of the 91 patients recruited (F=47, CVP=44), 84 completed the questionnaire at baseline, 74 during treatment, and 41 after treatment. All FS were high at baseline (70–90) and varied from 1 to 12 points during study. All FS improved during treatment, except CF and QL in the F group which remained unchanged, and RF and SF in the CVP group which deteriorated. The difference between groups reached statistical significance for SF (p=0.0076) but not for RF (p=0.4597). All SSI scores were low (10 to 40) and varied only slightly during the trial. Most scores improved except DY and CO in the F group and NV, CO, DI, and FI in the CVP group. CONCLUSIONS: QoL was high in these patients. The higher incidence of nausea, vomiting and alopecia observed in the CVP group may explain the difference observed for SF, and to a lesser extent RF.